• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Survival trends of US dialysis patients with heart failure: 1995 to 2005.美国心衰透析患者的生存趋势:1995 年至 2005 年。
Clin J Am Soc Nephrol. 2011 Aug;6(8):1982-9. doi: 10.2215/CJN.01130211. Epub 2011 Jul 22.
2
Survival advantage of hemodialysis relative to peritoneal dialysis in patients with end-stage renal disease and congestive heart failure.终末期肾病合并充血性心力衰竭患者行血液透析相对腹膜透析的生存优势。
Kidney Int. 2011 Nov;80(9):970-977. doi: 10.1038/ki.2011.233. Epub 2011 Jul 20.
3
Mortality in Incident Maintenance Dialysis Patients Versus Incident Solid Organ Cancer Patients: A Population-Based Cohort.维持性透析患者与实体器官恶性肿瘤患者的死亡率比较:一项基于人群的队列研究。
Am J Kidney Dis. 2019 Jun;73(6):765-776. doi: 10.1053/j.ajkd.2018.12.011. Epub 2019 Feb 6.
4
Impact of dialysis modality on survival of new ESRD patients with congestive heart failure in the United States.透析方式对美国新发充血性心力衰竭终末期肾病患者生存率的影响。
Kidney Int. 2003 Sep;64(3):1071-9. doi: 10.1046/j.1523-1755.2003.00165.x.
5
Temporal Trends in Incident Mortality in Dialysis Patients: Focus on Sex and Racial Disparities.透析患者发病死亡率的时间趋势:关注性别和种族差异。
Am J Nephrol. 2019;49(3):241-253. doi: 10.1159/000497446. Epub 2019 Feb 28.
6
[Current peritoneal dialysis compared with haemodialysis: medium-term survival analysis of incident dialysis patients in the Canary Islands in recent years].[近年来加那利群岛新入透析患者的中期生存分析:当前腹膜透析与血液透析的比较]
Nefrologia. 2011;31(2):174-84. doi: 10.3265/Nefrologia.pre2011.Jan.10743.
7
Differential impact of smoking on mortality and kidney transplantation among adult Men and Women undergoing dialysis.吸烟对接受透析的成年男性和女性死亡率及肾移植的不同影响。
BMC Nephrol. 2016 Jul 26;17:95. doi: 10.1186/s12882-016-0311-x.
8
Survival analysis of pediatric dialysis patients in Taiwan.台湾地区儿科透析患者的生存分析。
Nephrology (Carlton). 2012 Sep;17(7):621-7. doi: 10.1111/j.1440-1797.2012.01613.x.
9
Survival after the onset of congestive heart failure in Framingham Heart Study subjects.弗明汉心脏研究受试者出现充血性心力衰竭后的生存率。
Circulation. 1993 Jul;88(1):107-15. doi: 10.1161/01.cir.88.1.107.
10
Impact of dialysis modality on the survival of end-stage renal disease patients with or without cardiovascular disease.透析方式对有或无心血管疾病的终末期肾病患者生存的影响。
J Nephrol. 2013 Mar-Apr;26(2):331-41. doi: 10.5301/jn.5000149. Epub 2012 Mar 30.

引用本文的文献

1
Impact of dialysis modality choice on the survival of end-stage renal disease patients with congestive heart failure in southern China: A retrospective cohort study.透析方式选择对中国南方终末期肾病合并充血性心力衰竭患者生存的影响:一项回顾性队列研究。
Front Med (Lausanne). 2022 Oct 17;9:898650. doi: 10.3389/fmed.2022.898650. eCollection 2022.
2
Hypoalbuminaemia and One-Year Mortality in Haemodialysis Patients with Heart Failure: A Cohort Analysis.血液透析心力衰竭患者的低白蛋白血症与一年死亡率:一项队列分析
J Clin Med. 2021 Sep 29;10(19):4518. doi: 10.3390/jcm10194518.
3
Race and Mortality in CKD and Dialysis: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study.种族与慢性肾脏病和透析患者的死亡率:来自慢性肾功能不全队列(CRIC)研究的发现。
Am J Kidney Dis. 2020 Mar;75(3):394-403. doi: 10.1053/j.ajkd.2019.08.011. Epub 2019 Nov 12.
4
Therapeutic Approach to Patients with Heart Failure with Reduced Ejection Fraction and End-stage Renal Disease.射血分数降低的心力衰竭合并终末期肾病患者的治疗方法
Curr Cardiol Rev. 2018 Mar 14;14(1):60-66. doi: 10.2174/1573403X14666180123164916.
5
Prevalence and variation of Chronic Kidney Disease in the Irish health system: initial findings from the National Kidney Disease Surveillance Programme.爱尔兰医疗系统中慢性肾脏病的患病率及变化:国家肾脏疾病监测计划的初步结果
BMC Nephrol. 2014 Nov 25;15:185. doi: 10.1186/1471-2369-15-185.
6
Decision making in advanced heart failure: a scientific statement from the American Heart Association.晚期心力衰竭的决策制定:美国心脏协会的科学声明
Circulation. 2012 Apr 17;125(15):1928-52. doi: 10.1161/CIR.0b013e31824f2173. Epub 2012 Mar 5.

本文引用的文献

1
Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial.替米沙坦联合血管紧张素转换酶抑制剂对慢性心力衰竭血液透析患者死亡率和发病率的影响:一项双盲、安慰剂对照试验。
J Am Coll Cardiol. 2010 Nov 16;56(21):1701-8. doi: 10.1016/j.jacc.2010.03.105.
2
Race, gender, and mortality in adults > or =65 years of age with incident heart failure (from the Cardiovascular Health Study).≥65岁成年人心力衰竭患者的种族、性别与死亡率(来自心血管健康研究)
Am J Cardiol. 2009 Apr 15;103(8):1120-7. doi: 10.1016/j.amjcard.2008.12.043.
3
K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients.《K/DOQI 透析患者心血管疾病临床实践指南》
Am J Kidney Dis. 2005 Apr;45(4 Suppl 3):S1-153.
4
Improvements in dialysis patient mortality are associated with improvements in urea reduction ratio and hematocrit, 1999 to 2002.1999年至2002年期间,透析患者死亡率的改善与尿素清除率及血细胞比容的改善相关。
Am J Kidney Dis. 2005 Jan;45(1):127-35. doi: 10.1053/j.ajkd.2004.09.023.
5
A randomized evaluation of two health care quality improvement program (HCQIP) interventions to improve the adequacy of hemodialysis care of ESRD patients: feedback alone versus intensive intervention.一项关于两种医疗质量改进计划(HCQIP)干预措施以提高终末期肾病(ESRD)患者血液透析护理充分性的随机评估:单纯反馈与强化干预。
J Am Soc Nephrol. 2004 Mar;15(3):754-60. doi: 10.1097/01.asn.0000115701.51613.d7.
6
Erythropoietin should be part of congestive heart failure management.促红细胞生成素应成为充血性心力衰竭治疗的一部分。
Kidney Int Suppl. 2003 Nov(87):S40-7. doi: 10.1046/j.1523-1755.64.s87.7.x.
7
Developing clinical performance measures based on the Dialysis Outcomes Quality Initiative Clinical Practice Guidelines: process, outcomes, and implications.基于透析结果质量改进临床实践指南制定临床绩效指标:过程、结果及影响
Am J Kidney Dis. 2003 Oct;42(4):806-12. doi: 10.1016/s0272-6386(03)00867-9.
8
Impact of dialysis modality on survival of new ESRD patients with congestive heart failure in the United States.透析方式对美国新发充血性心力衰竭终末期肾病患者生存率的影响。
Kidney Int. 2003 Sep;64(3):1071-9. doi: 10.1046/j.1523-1755.2003.00165.x.
9
National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification.美国国家肾脏基金会慢性肾脏病实践指南:评估、分类与分层
Ann Intern Med. 2003 Jul 15;139(2):137-47. doi: 10.7326/0003-4819-139-2-200307150-00013.
10
Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial.卡维地洛可提高扩张型心肌病透析患者的两年生存率:一项前瞻性、安慰剂对照试验。
J Am Coll Cardiol. 2003 May 7;41(9):1438-44. doi: 10.1016/s0735-1097(03)00241-9.

美国心衰透析患者的生存趋势:1995 年至 2005 年。

Survival trends of US dialysis patients with heart failure: 1995 to 2005.

机构信息

Regional Kidney Centre, Department of Medicine, Letterkenny General Hospital, Letterkenny, Donegal, Ireland.

出版信息

Clin J Am Soc Nephrol. 2011 Aug;6(8):1982-9. doi: 10.2215/CJN.01130211. Epub 2011 Jul 22.

DOI:10.2215/CJN.01130211
PMID:21784821
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3359531/
Abstract

BACKGROUND AND OBJECTIVES

Congestive heart failure (CHF) is a major risk factor for death in end-stage kidney disease; however, data on prevalence and survival trends are limited. The objective of this study was to determine the prevalence and mortality effect of CHF in successive incident dialysis cohorts.

DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a population-based cohort of incident US dialysis patients (n = 926,298) from 1995 to 2005. Age- and gender-specific prevalence of CHF was determined by incident year, whereas temporal trends in mortality were compared using multivariable Cox regression.

RESULTS

The prevalence of CHF was significantly higher in women than men and in older than younger patients, but it did not change over time in men (range 28% to 33%) or women (range 33% to 36%). From 1995 to 2005, incident death rates decreased for younger men (≤70 years) and increased for older men (>70 years). For women, the pattern was similar but less impressive. During this period, the adjusted mortality risks (relative risk [RR]) from CHF decreased in men (from RR = 1.06 95% Confidence intervals (CI) 1.02-1.11 in 1995 to 0.91 95% CI 0.87-0.96 in 2005) and women (from RR = 1.06 95% CI 1.01-1.10 in 1995 to 0.90 95% CI 0.85-0.95 in 2005 compared with referent year 2000; RR = 1.00). The reduction in mortality over time was greater for younger than older patients (20% to 30% versus 5% to 10% decrease per decade).

CONCLUSIONS

Although CHF remains a common condition at dialysis initiation, mortality risks in US patients have declined from 1995 to 2005.

摘要

背景和目的

充血性心力衰竭(CHF)是终末期肾病患者死亡的主要危险因素;然而,关于患病率和生存趋势的数据有限。本研究的目的是确定连续发生的透析队列中 CHF 的患病率和死亡率的影响。

设计、地点、参与者和测量方法:这是一项基于人群的美国透析患者(n=926298)的新发病例队列,研究时间为 1995 年至 2005 年。按发病年份确定 CHF 的年龄和性别特异性患病率,使用多变量 Cox 回归比较死亡率的时间趋势。

结果

女性 CHF 的患病率明显高于男性,老年患者高于年轻患者,但男性(范围 28%至 33%)或女性(范围 33%至 36%)患病率并未随时间变化。从 1995 年到 2005 年,年轻男性(≤70 岁)的新发病死率下降,而老年男性(>70 岁)的新发病死率上升。对于女性,情况类似,但不太明显。在此期间,男性的调整死亡率风险(相对风险[RR])从 CHF 降低(从 1995 年的 RR=1.06,95%置信区间[CI]1.02-1.11 降至 2005 年的 RR=0.91,95%CI0.87-0.96),女性(从 1995 年的 RR=1.06,95%CI1.01-1.10 降至 2005 年的 RR=0.90,95%CI0.85-0.95,与参考年 2000 年相比;RR=1.00)。与年龄较大的患者相比,年轻患者的死亡率随时间下降幅度更大(每十年下降 20%至 30%,而下降 5%至 10%)。

结论

尽管 CHF 仍是透析开始时的常见病症,但美国患者的死亡率自 1995 年至 2005 年已有所下降。